CCND1 and breast carcinoma: Beyond its therapeutic potential, circFOXK2 expression could serve as a biomarker to identify patients who are most likely to benefit from circFOXK2-based therapies, particularly those with high circFOXK2 and CCND1 expression and resistance to endocrine treatments in breast cancer.